Tackling DNA damage repair mechanisms —a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma
SummaryMolecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targetinggBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyondgBRCA and olaparib. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 21, 2020 Category: Cancer & Oncology Source Type: research

Cytoreductive surgery and HIPEC in colorectal cancer —did we get hold of the wrong end of the stick?
SummaryCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a  multimodal treatment approach combining surgical interventions of varying extent with administration of heated cytostatic drugs flushed through the abdominal cavity. Hitherto, this treatment has been popular for peritoneal metastasis (PM), e.g. from colorectal cancer (CRC). Recent randomized contr olled trials (RCT) question the benefit of HIPEC in its present form for CRC treatment and raise fundamental issues, eliciting discussions and expert statements regarding HIPEC relevance and interpretation of these results. Unfort...
Source: Memo - Magazine of European Medical Oncology - October 20, 2020 Category: Cancer & Oncology Source Type: research

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
ConclusionUpregulation of WNT3 and LEF1 could be used as helpful and specific markers to distinguish our CLL patients. Low WNT3 and LEF1 expression is associated with shortened survival in CLL patients. These results indicate that WNT3 and LEF1 represent an attractive therapeutic target for future therapies in Egyptian CLL patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 13, 2020 Category: Cancer & Oncology Source Type: research

Report from the Virtual Edition of the 25th European Hematology Association (EHA), Annual Congress 11th –21st June 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 9, 2020 Category: Cancer & Oncology Source Type: research

A  case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature
SummaryThe prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a  patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 29, 2020 Category: Cancer & Oncology Source Type: research

Autologous stem cell transplantation in light-chain amyloidosis
SummaryTreatment of patients with light-chain amyloidosis (AL amyloidosis) has changed over the last 20  years, and early mortality rates have decreased with prolongation of survival. However, many patients are not cured with conventional therapy. Therefore, all patients should be assessed at diagnosis to determine eligibility for autologous stem cell transplantation (ASCT) since high-dose melphalan and ASCT have been shown to induce long-term hematologic and clinical responses with treatment-related mortality (TRM)
Source: Memo - Magazine of European Medical Oncology - September 20, 2020 Category: Cancer & Oncology Source Type: research

Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?
SummaryPeritoneal carcinomatosis from colorectal cancer is associated with a  poor prognosis and is usually treated with systemic chemotherapy and immunotherapy alone. In patients with isolated peritoneal carcinomatosis (PC) without nonperitoneal metastases, however, cytoreductive surgery (CRS) has been shown to significantly improve outcome and to achieve even cure in sele cted patients in combination with systemic therapy. The additional use of a hyperthermic intraperitoneal chemotherapy (HIPEC) is primarily indicated to control microscopical residual tumor tissue in the peritoneal cavity after successful CRS. ...
Source: Memo - Magazine of European Medical Oncology - September 17, 2020 Category: Cancer & Oncology Source Type: research

Ovarian transposition
SummaryCytotoxic chemotherapy regimens and radiotherapy can lead to acute ovarian failure, premature ovarian insufficiency and menopause. Fertility preservation options before radiotherapy include ovarian transposition, where one or both ovaries are placed outside the radiation field. However, the efficacy of ovarian transposition is questioned, as the conservation of ovarian function varies between 17 and 95% in the literature. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 17, 2020 Category: Cancer & Oncology Source Type: research

Creating the “new normal” post-Coronavirus world—web-communication replacing face-to-face interaction
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

News from ASH 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

Managing an oncology clinic during the COVID-19 pandemic —how we did it in Sarajevo?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

Rectal cancer: latest developments and innovative new treatment concepts
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

Treatment of advanced melanoma
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

San Antonio 2019: interesting topics for daily clinical practice in breast cancer
SummaryThe San Antonio Breast Cancer Summit is one of the most important meetings worldwide for physicians who treat breast cancer. As traveling there is always somewhat of an adventure due to the distance and the time of the year (winter) and access is not easy for all physicians, the goal of this article is to provide an overview of the presentations dealing with hormone-receptor-positive breast cancer, capecitabine, prevention, and hormone replacement therapy. Data and results should positively influence daily practice. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2020 Category: Cancer & Oncology Source Type: research

memo —publisher’s report 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 30, 2020 Category: Cancer & Oncology Source Type: research

Transoral robotic surgery in head and neck cancer
SummaryRobotic surgery in the field of head and neck cancer was initiated at the beginning of this century. In the last decade, transoral robotic surgery (TORS) had to prove its oncological equivalence to standardised conservative treatment regimens like radiotherapy and radiochemotherapy and to other transoral or open surgical procedures. The amount of data on oncological efficacy, cost effectiveness and long-term outcomes has continued to increase over the last few years. The transoral approach enables minimally invasive tumour resection, which helps to minimize functional postoperative deficits. Compared with traditiona...
Source: Memo - Magazine of European Medical Oncology - August 27, 2020 Category: Cancer & Oncology Source Type: research

The future of combination therapies in advanced melanoma
SummaryThe combination of Cytotoxic T-Lymphozyte Antigen-4 (CTLA ‑4) and Programmed death-1 (PD‑1) antibodies and the combination of BRAF and MEK inhibitors are the current clinical standards for combination immune and targeted therapy for melanoma, respectively. The success of these therapies has stimulated research into novel drug combinations for melanom a, of which a large majority are based on combination with PD‑1 or PD-Ligand 1 (PD-L1) blocking drugs. Thus, the aim is to provide an overview of the most important combination strategies in late stage clinical development and an outlook on dru...
Source: Memo - Magazine of European Medical Oncology - August 13, 2020 Category: Cancer & Oncology Source Type: research

Clinical characteristics and treatment of delirium in palliative care settings
SummaryDelirium is commonly seen in palliative care. It usually develops over a  short period of time and is characterized by a disturbance of attention and awareness. As delirium is associated with increased mortality, prevention and early identification of this severe neurocognitive disorder is of high clinical relevance. This paper provides a brief overview of risk factor s, preventive measures, current screening and diagnostic procedures, as well as nonpharmacological and pharmacological treatment options of delirium in the palliative care setting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 13, 2020 Category: Cancer & Oncology Source Type: research

Report from the ASCO Virtual Congress, May 29th – 31st 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 5, 2020 Category: Cancer & Oncology Source Type: research

Sarcopenia in cancer —a focus on elderly cancer patients
SummaryGeriatric assessments, nutritional counseling and monitoring of muscle health before and during therapy are of high clinical significance in the management of elderly cancer patients. Criteria, data and cut-offs characterizing cancer-related geriatric sarcopenia are sparse and no consensus about definitions exists to date. We hence highlight a need for clinical trials focusing on sarcopenia in elderly cancer patients, based on its high prevalence and potential negative consequences on therapy outcomes, mortality, quality of life and physical mobility. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 28, 2020 Category: Cancer & Oncology Source Type: research

San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor  2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)
SummaryAt the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase  3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a  pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was m...
Source: Memo - Magazine of European Medical Oncology - July 12, 2020 Category: Cancer & Oncology Source Type: research

Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
SummaryBackgroundColorectal cancer is the most common origin of peritoneal metastasis in total, with 15% metastasizing to the peritoneum. In order to provide satisfactory peritoneal recurrence-free survival and low morbidity and mortality rates appropriate patient selection is crucial.MethodsLiterature research (Pubmed) from 2013 to 2020 was performed including the terms “colorectal”, “peritoneal”, “metastasis”, “cytoreductive surgery”, “HIPEC” and “patient selection”.Results and conclusionDespite predictive models the rate of non-therapeutic laparotom...
Source: Memo - Magazine of European Medical Oncology - July 12, 2020 Category: Cancer & Oncology Source Type: research

Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up
SummaryMonoclonal gammopathy of undetermined significance (MGUS) is a  premalignant hematological condition arising from B‑cells, characterized by the presence of monoclonal immunoglobulin production, also known as paraprotein. It is found in up to 3% of individuals over the age of 50 years. The overall progression rate is low at around 1% per year, with most pati ents progressing to multiple myeloma (MM). Other diseases that may arise from MGUS include non-Hodgkin lymphomas, Waldenström macroglobulinemia, amyloid light-chain (AL) amyloidosis, POEMS (polyneuropathy, organomegaly, endocrinopathy, M‑protei...
Source: Memo - Magazine of European Medical Oncology - July 12, 2020 Category: Cancer & Oncology Source Type: research

Patient-reported outcomes and psycho-oncological screening in hematology: a  practical example of routine electronic monitoring
SummaryPatient-reported outcomes (PROs) have gained increasing importance in oncology. PROs can supplement medical treatment with important information about the patient ’s quality of life (QoL), which is typically assessed using standardized questionnaires. PROs capture the symptomatology and functional impairments as perceived by the patient without further interpretation by another party. In this article, we describe how routinely assessed electronic PROs (ePRO s) at the outpatient unit of the Department of Hematology Innsbruck complement the Austrian Myeloma Registry (AMR) and clinical routine. There is a br...
Source: Memo - Magazine of European Medical Oncology - July 2, 2020 Category: Cancer & Oncology Source Type: research

Four lines of immunochemotherapy combinations in a  young patient with an aggressive metastatic colorectal cancer
We report on a  42-year-old woman with colorectal cancer of the sigmoid colon with synchronous pulmonary metastases being treated since June of 2016. With a poorly differentiated, KRAS, NRAS and BRAF wildtype cancer and an advanced stage of the disease we look back to almost four years of treatment and a sequen ce consisting of four lines of polychemotherapy. Dynamic treatment without achieving relevant treatment-free periods resulted in a satisfying quality of life and prolonged overall survival. Exceptional cases in young and very fit patients support the benefit of a more aggressive treatment st...
Source: Memo - Magazine of European Medical Oncology - June 29, 2020 Category: Cancer & Oncology Source Type: research

Future perspectives of fertility preservation in women
SummaryFertility preservation in women has become well established over the last two decades. Nevertheless, options for cancer survivors need to be improved to regain ovarian functioning, ideally leading to pregnancy and live birth. Techniques to protect the ovary from the damage of cytotoxic agents, to improve the survival of follicles in the ovarian graft, and to minimize the risk of re-seeding malignant cells after ovarian tissue transplantation are the object of current research all over the world. The demand for fertility preservation procedures in patients with benign diseases like systemic lupus erythematosus before...
Source: Memo - Magazine of European Medical Oncology - June 22, 2020 Category: Cancer & Oncology Source Type: research

Homologous recombination deficiency in breast cancer
SummaryBRCA mutation-related DNA repair deficiencies increase the individual sensitivity to DNA-targeting agents. Therefore, the patient ’sBRCA mutational status is evaluated in clinical practice as a  predictive marker in response to platinum salts and poly-ADP-ribose polymerase (PARP) inhibitors for breast cancer treatment. A substantial subset ofBRCAwild-type breast cancer lesions, however, share both prominent molecular characteristics and clinical behavior patterns with cancer that harborsBRCA mutations, including DNA repair deficiencies. Also referred to as “BRCAness”, this observation is ...
Source: Memo - Magazine of European Medical Oncology - June 8, 2020 Category: Cancer & Oncology Source Type: research

Geriatric oncology: questions, answers and guidelines
ConclusionThe ASCO has recognized the optimization of cancer therapy for elderly patients as a  priority. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 8, 2020 Category: Cancer & Oncology Source Type: research

Particle therapy in head and neck cancer —expanding therapeutic options
SummaryThe management of head and neck tumors is challenging and requires a  multidisciplinary approach. Besides the common histology of squamous cell cancer, other histologies like adenoid cystic carcinoma, mucosal melanoma, and adenocarcinoma are often present. These tumors are radioresistant and need high radiation doses. Photon beam therapy is often limited by the norm al tissue tolerance, and particle therapy using protons or carbon ions is a valuable treatment option. Due to their dosimetric advantages, protons enable deposition of high tumor doses, while optimally sparing the surrounding tissue. Carbon ion...
Source: Memo - Magazine of European Medical Oncology - June 3, 2020 Category: Cancer & Oncology Source Type: research

Hepatocellular carcinoma
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 31, 2020 Category: Cancer & Oncology Source Type: research

Epithelial ovarian cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 31, 2020 Category: Cancer & Oncology Source Type: research

An update from the 2019 ESMO meeting
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 31, 2020 Category: Cancer & Oncology Source Type: research

Diagnostic and therapeutic management of sarcoma patients
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 31, 2020 Category: Cancer & Oncology Source Type: research

Rectal cancer among younger Egyptian patients —clinico-pathological features and oncologic outcomes: A single institution experience
SummaryOur younger rectal carcinoma cases had poorer pathologic criteria but the therapy was the crucial factor affecting their survival. Full course of radiotherapy was crucial for better OS of the younger group (P = 0.014), while chemotherapy was crucial for better DFS/PFS in both the young and old age groups (P = 0.00). (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 25, 2020 Category: Cancer & Oncology Source Type: research

Myeloid diseases —Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments
SummaryThe recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients suffering from the disease. Interesting updates were presented on new kinase inhibitors (TKI) demonstrating great potential with low toxicities in heavily pretreated patients. Moreover, the 10-year follow-up data of the ENESTnd Study, comparing 2nd generation (2ndG) TKI nilotinib with imatinib showed a  continuous benefit of the 2ndG TKI in achieving deeper molecular respon...
Source: Memo - Magazine of European Medical Oncology - May 25, 2020 Category: Cancer & Oncology Source Type: research

Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma
ConclusionLEAM is more effective than CCVP-16 in ASCT for lymphoma, especially Hodgkin lymphoma, and has a  comparable toxicity profile. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 24, 2020 Category: Cancer & Oncology Source Type: research

Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors
SummaryStereotactic body radiotherapy (SBRT) delivers precise concentric radiation to a  tumor. It is well established that local control depends on the biologically effective dose (BED) delivered, with BED10 of ≥100 as a significant predictor of local control. The aim of this study was to evaluate factors associated with overall survival (OS) in inoperable lung cancer cases treate d with SBRT. From 2013 to 2016, 22 patients with inoperable lung cancer treated with SBRT who could be followed up until their time of death were retrospectively enrolled. Data on sex, age, dose (Gray), number of fractions, BED...
Source: Memo - Magazine of European Medical Oncology - May 24, 2020 Category: Cancer & Oncology Source Type: research

ASH highlights 2019: “aggressive B-cell lymphoma”
SummaryDespite its significant cure rate, diffuse large B ‑cell lymphoma (DLBCL) remains a tumor entity of unmet medical need. The 2019 meeting of the American Society of Hematology (ASH) in Orlando, Florida, presented numerous directions, whereby clinicians may expect practice-changing innovations soon or in the near future. In this ASH highlight featu re on “aggressive B‑cell lymphoma”, a selection of prominent findings will be summarized. Targeted therapeutics try to meet the needs of patients subgroups that would benefit, and novel immune oncology agents now represent established treatment pri...
Source: Memo - Magazine of European Medical Oncology - May 19, 2020 Category: Cancer & Oncology Source Type: research

New systemic treatment options in mycosis fungoides and S ézary syndrome
SummaryCutaneous T cell lymphomas (CTCL) are a heterogeneous group of rare non-Hodgkin lymphomas. The most common type of CTCL is Mycosis fungoides (MF). Much less common but clinically and histopathologically related to MF is S ézary syndrome (SS). CTCL are incurable and associated with a reduced quality of life. While early stage MF has a good prognosis and is usually treated with skin directed therapies, advanced-stages require systemic therapies, including retinoids, interferon, cytotoxic chemotherapeutic drugs, low-do se methotrexate, histone deacetylase inhibitors and alemtuzumab. However, relapses are frequen...
Source: Memo - Magazine of European Medical Oncology - May 19, 2020 Category: Cancer & Oncology Source Type: research

Fertility preservation procedures in girls, adolescents and women
SummaryFertility preservation has become an integral part of standard treatment for young patients with planned gonadotoxic therapy. The decision-making process is an interdisciplinary challenge to both oncologists and radiotherapists involved in the process of diagnosis and treatment. Nevertheless, even today, not every patient receives adequate counselling about fertility preserving techniques. Current data on the options of fertility preservation for women, including cryopreservation of oocytes, embryos, ovarian tissue, transposition of ovaries and medical treatment, are summarized in this review. (Source: Memo - Magazi...
Source: Memo - Magazine of European Medical Oncology - May 19, 2020 Category: Cancer & Oncology Source Type: research

Fine-tuning front-line therapy in chronic lymphocytic leukemia
SummaryA  deeper understanding of disease biology and the advent of targeted drugs have implemented chemotherapy-free treatment options in chronic lymphocytic leukemia (CLL). With consistently superior outcome data and good tolerability, the Bruton’s kinase inhibitor ibrutinib as well as the B‑cell lymp homa 2 inhibitor venetoclax +/− CD20 antibody have recently been licensed for first-line treatment independently of TP53 status and are currently recommended as therapy of choice in most patient subgroups according to international management guidelines. Survival curves, however, have not reache...
Source: Memo - Magazine of European Medical Oncology - May 18, 2020 Category: Cancer & Oncology Source Type: research

Nutritional management during treatment for head and neck cancer
ConclusionIt is important to determine the best course of management to maintain body weight and reduce typical adverse effects of malnutrition to improve quality of life. All patients at any stage of their treatment should receive intensive dietary counseling. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 13, 2020 Category: Cancer & Oncology Source Type: research

Highlights of ASH  2019—multiple myeloma
SummaryThe 2019 meeting of the American Society of Hematology (ASH) was dominated by new data from clinical research; effective combinations of mostly recently approved drugs and studies with new promising agents and treatment concepts, currently in the preapproval status, were on the forefront of attendee ’s interest. Results from the ALCYONE study revealed a significant survival advantage with the addition of daratumumab, thus, highlighting the therapeutic potential of monoclonal antibodies. These antibodies are becoming standard combination partners for all lines of therapy. Presently, it remain s unclear whe...
Source: Memo - Magazine of European Medical Oncology - May 12, 2020 Category: Cancer & Oncology Source Type: research

Systemic therapy for metastatic salivary gland tumors —challenges and novel concepts
SummarySalivary gland cancers (SGC) are a  rare and heterogeneous group of malignancies. Most frequently tumors arise in the parotid gland. The most common histologic subtypes are adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC). Rare subtypes include salivary ductal carcinoma (SDC), mammary analogue secretory carcinoma (M ASC) and adenocarcinoma not other specified (AC NOS). For locally advanced or metastatic disease, chemotherapy has been the mainstay of therapy. The course of disease differs markedly between the subtypes, especially ACC usually presents as slowly progressing disease. Due to the rar...
Source: Memo - Magazine of European Medical Oncology - May 12, 2020 Category: Cancer & Oncology Source Type: research

Circumnavigating the challenges of COVID-19 in oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 6, 2020 Category: Cancer & Oncology Source Type: research

Treatment options in early triple-negative breast cancer
SummaryWith a  main focus on the early stage triple-negative breast cancer (TNBC), new data on immunotherapy in combination with chemotherapy, the role of capecitabine, the potential of circulating tumor DNA as a predictive tool in the postneoadjuvant setting and new treatment approaches were presented and disc ussed at the San Antonio Breast Cancer Symposium (SABCS) 2019. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 6, 2020 Category: Cancer & Oncology Source Type: research

ESMO 2019 —personal highlights in gastrointestinal cancer
This article summarizes important highlights regarding gastrointestinal cancer at the 2019 ESMO annual meeting. The choice of the abstracts was based on a personal view with a focus on different tumor entities of the gastrointestinal tract. Precision-medicine-guided therapy for cancer entities was one of the main topics at this year ’s ESMO. Furthermore, circulating tumor DNA (ctDNA) by performing liquid biopsy was again another hot topic, especially in guiding adjuvant chemotherapy in stage III colorectal cancer (CRC) patients. Finally, hope was stirred up again for immunotherapy in the indication of first-line...
Source: Memo - Magazine of European Medical Oncology - April 21, 2020 Category: Cancer & Oncology Source Type: research

Homologous recombination deficiency in epithelial ovarian cancer
SummarySince the introduction of poly-ADP-ribose polymerase (PARP) inhibitor therapy for epithelial ovarian cancer (EOC) patients, testing for aberrations of homologous recombination (HR) repair as a predictive biomarker of therapy response has become an area of particular clinical interest. As HR represents a  crucial repair pathway of otherwise possibly lethal DNA double strand breaks, its deficiency triggers a phenotypic behavior of tumor cells resulting in the accumulation of genetic damage. PARP inhibitors target this emerging genomic instability by fostering DNA strand breaks. Whereas testing for mutations ...
Source: Memo - Magazine of European Medical Oncology - April 20, 2020 Category: Cancer & Oncology Source Type: research

Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma
SummaryApproximately 20% of locoregional colorectal carcinoma (CRC) relapse after standard of care treatment. Therefore, it is necessary to personalize our adjuvant strategies and define this subgroup, which remains at high risk after treatment. Circulating tumour DNA (ctDNA) is cell-free DNA from apoptotic cancer cells, which carries the whole genome information of the primary tumour and has emerged as good candidate to guide our therapy decisions in the future. It was shown that high levels of ctDNA after adjuvant chemotherapy is a  poor prognostic factor. Moreover, it was presented at ESMO 2019 in Barcelona that pa...
Source: Memo - Magazine of European Medical Oncology - April 15, 2020 Category: Cancer & Oncology Source Type: research